Established in 2013, April Bio has developed global innovative new drugs in various therapeutic areas using its own human antibody library (HuDVFab) technology and SAFA (Serum Albumin Fragment Associated), a sustained platform technology that can increase the half-life of antibody fragment utilization. It is a company specializing in new antibody drugs.
April Bio is preparing for phase 1 clinical trial in the United States this year, APB-A1, a preclinical inflammatory autoimmune disease treatment (IL-18 target), APB-R3, male infertility treatment (FSH target) APB -R2, etc. are being developed.
Recently, April Bio decided to issue a paid-in capital increase of 10 billion won worth to a third party for Yuhan Corporation.
In 2020, it attracted 18 billion won worth of Series B investment, and at this time Yuhan Corporation as a strategic investor (SI) invested 3 billion won in April Bio to acquire a 4.89% stake.
Since then, Yuhan Corporation and April Bio have signed a joint research and new drug development business agreement and are strengthening research cooperation, and the two companies are further strengthening the partnership through additional investment.
Yuhan said, “The reason we made additional investments following the existing strategic investor (SI) is because the excellence of SAFA (Serum Albumin Fragment Associated), an independent platform technology owned by April Bio, was recognized.” I will do it,” he said.
Meanwhile, April Bio is preparing for a special listing on the KOSDAQ market this year through technology evaluation, and major financial investors are LB Investment, TS Investment, Hana Financial Investment, Ebest Investment Securities, SJ Investment Partners, Daekyo Investment, Mirae Equity Partners, SM Sino Technology Investment, BSK Investment, Wooshin Venture Investment, and Kolon Investment.